Literature DB >> 30605237

MicroRNA replacement therapy in cancer.

Homa Mollaei1, Reza Safaralizadeh2, Zeinab Rostami3.   

Abstract

Despite the recent progress in cancer management approaches, the mortality rate of cancer is still growing and there are lots of challenges in the clinics in terms of novel therapeutics. MicroRNAs (miRNA) are regulatory small noncoding RNAs and are already confirmed to have a great role in regulating gene expression level by targeting multiple molecules that affect cell physiology and disease development. Recently, miRNAs have been introduced as promising therapeutic targets for cancer treatment. Regulatory potential of tumor suppressor miRNAs, which enables regulation of entire signaling networks within the cells, makes them an interesting option for developing cancer therapeutics. In this regard, over recent decades, scientists have aimed at developing powerful and safe targeting approaches to restore these suppressive miRNAs in cancerous cells. The present review summarizes the function of miRNAs in tumor development and presents recent findings on how miRNAs have served as therapeutic agents against cancer, with a special focus on tumor suppressor miRNAs (mimics). Moreover, the latest investigations on the therapeutic strategies of miRNA delivery have been presented.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer therapy; miRNA delivery; miRNA replacement; microRNA; tumor suppressor miRNA

Mesh:

Substances:

Year:  2019        PMID: 30605237     DOI: 10.1002/jcp.28058

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  58 in total

Review 1.  MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

2.  The combined restoration of miR-424-5p and miR-142-3p effectively inhibits MCF-7 breast cancer cell line via modulating apoptosis, proliferation, colony formation, cell cycle and autophagy.

Authors:  Narges Dastmalchi; Reza Safaralizadeh; Seyed Mahdi Banan Khojasteh; Mahdi Abdoli Shadbad; Mohammad Ali Hosseinpourfeizi; Shirin Azarbarzin; Ali Rajabi; Behzad Baradaran
Journal:  Mol Biol Rep       Date:  2022-06-06       Impact factor: 2.742

Review 3.  Non-Coding RNAs: New Dawn for Diabetes Mellitus Induced Erectile Dysfunction.

Authors:  Wenchao Xu; Hongyang Jiang; Jihong Liu; Hao Li
Journal:  Front Mol Biosci       Date:  2022-06-22

4.  miR-212-5p inhibits nasopharyngeal carcinoma progression by targeting METTL3.

Authors:  Hongyu Zhou; Nana Zhang
Journal:  Open Med (Wars)       Date:  2022-07-12

5.  MiR-379-5p inhibits the proliferation, migration, and invasion of breast cancer by targeting KIF4A.

Authors:  Ke Yang; Danyang Li; Weihui Jia; Yanmei Song; Ningxin Sun; Jiemin Wang; Hongli Li; Chonggao Yin
Journal:  Thorac Cancer       Date:  2022-05-24       Impact factor: 3.223

Review 6.  Kaempferol: A potential agent in the prevention of colorectal cancer.

Authors:  Hamid Reza Nejabati; Leila Roshangar
Journal:  Physiol Rep       Date:  2022-10

Review 7.  Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era.

Authors:  Xiaoran Zhang; Christopher P Deibert; Wi-Jin Kim; Emade Jaman; Aparna V Rao; Michael T Lotze; Nduka M Amankulor
Journal:  Cancer Gene Ther       Date:  2020-08-05       Impact factor: 5.987

8.  MicroRNA-937 inhibits the malignant phenotypes of breast cancer by directly targeting and downregulating forkhead box Q1.

Authors:  Xiaoting Han; Xiaolong Guo; Wenzhen Zhang; Qiumei Cong
Journal:  Onco Targets Ther       Date:  2019-06-20       Impact factor: 4.147

Review 9.  MicroRNAs as regulators of brain function and targets for treatment of epilepsy.

Authors:  Gary P Brennan; David C Henshall
Journal:  Nat Rev Neurol       Date:  2020-06-16       Impact factor: 42.937

10.  Dual Regulation of miR-34a and Notch Signaling in Triple-Negative Breast Cancer by Antibody/miRNA Nanocarriers.

Authors:  Danielle M Valcourt; Emily S Day
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-09       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.